+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Obsessive-Compulsive Disorder Drugs Market 2024-2028

  • PDF Icon

    Report

  • 159 Pages
  • December 2023
  • Region: Global
  • TechNavio
  • ID: 5606268
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The obsessive-compulsive disorder drugs market is forecasted to grow by USD 348.54 mn during 2023-2028, accelerating at a CAGR of 5.93% during the forecast period. The report on the obsessive-compulsive disorder drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising prevalence of OCD, launch of new molecules, and increasing awareness programs for OCD.

The obsessive-compulsive disorder drugs market is segmented as below:

By Product

  • SSRI
  • TSA
  • Others

By Route Of Administration

  • Oral
  • Parentral

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)
This study identifies the increased use of off-label therapies as one of the prime reasons driving the obsessive-compulsive disorder drugs market growth during the next few years. Also, expanding research on first-in-class peptide therapeutics and increasing generic approvals will lead to sizable demand in the market.

The report on the obsessive-compulsive disorder drugs market covers the following areas:

  • Obsessive-compulsive disorder drugs market sizing
  • Obsessive-compulsive disorder drugs market forecast
  • Obsessive-compulsive disorder drugs market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading obsessive-compulsive disorder drugs market vendors that include Alembic Pharmaceuticals Ltd., Anant Pharmaceuticals Pvt. Ltd., Apotex Inc., BrainsWay Ltd., Dellwich Healthcare LLP, Eli Lilly and Co., Eridanus, flamingopharma.com, GlaxoSmithKline Plc, H Lundbeck AS, Jabs Biotech, Jazz Pharmaceuticals Plc, Kabir Lifesciences, Lepu Medical Technology Beijing Co. Ltd., Lifecare Neuro Products Ltd., Novartis AG, Omeros Corp., Pfizer Inc., SERVOMAX Ltd., Wellona Pharma, and Neurocon Inc.. Also, the obsessive-compulsive disorder drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary
1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by Product
Exhibit 06: Executive Summary - Chart on Market Segmentation by Route of Administration
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning
2 Market Landscape
2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics
3 Market Sizing
3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2023
3.4 Market outlook: Forecast for 2023-2028
Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
4 Historic Market Size
4.1 Global obsessive-compulsive disorder drugs market 2018 - 2022
Exhibit 18: Historic Market Size - Data Table on global obsessive-compulsive disorder drugs market 2018 - 2022 ($ million)
4.2 Product Segment Analysis 2018 - 2022
Exhibit 19: Historic Market Size - Product Segment 2018 - 2022 ($ million)
4.3 Route of Administration Segment Analysis 2018 - 2022
Exhibit 20: Historic Market Size - Route of Administration Segment 2018 - 2022 ($ million)
4.4 Geography Segment Analysis 2018 - 2022
Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
4.5 Country Segment Analysis 2018 - 2022
Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ million)
5 Five Forces Analysis
5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2023 and 2028
6 Market Segmentation by Product
6.1 Market segments
Exhibit 30: Chart on Product - Market share 2023-2028 (%)
Exhibit 31: Data Table on Product - Market share 2023-2028 (%)
6.2 Comparison by Product
Exhibit 32: Chart on Comparison by Product
Exhibit 33: Data Table on Comparison by Product
6.3 SSRI - Market size and forecast 2023-2028
Exhibit 34: Chart on SSRI - Market size and forecast 2023-2028 ($ million)
Exhibit 35: Data Table on SSRI - Market size and forecast 2023-2028 ($ million)
Exhibit 36: Chart on SSRI - Year-over-year growth 2023-2028 (%)
Exhibit 37: Data Table on SSRI - Year-over-year growth 2023-2028 (%)
6.4 TSA - Market size and forecast 2023-2028
Exhibit 38: Chart on TSA - Market size and forecast 2023-2028 ($ million)
Exhibit 39: Data Table on TSA - Market size and forecast 2023-2028 ($ million)
Exhibit 40: Chart on TSA - Year-over-year growth 2023-2028 (%)
Exhibit 41: Data Table on TSA - Year-over-year growth 2023-2028 (%)
6.5 Others - Market size and forecast 2023-2028
Exhibit 42: Chart on Others - Market size and forecast 2023-2028 ($ million)
Exhibit 43: Data Table on Others - Market size and forecast 2023-2028 ($ million)
Exhibit 44: Chart on Others - Year-over-year growth 2023-2028 (%)
Exhibit 45: Data Table on Others - Year-over-year growth 2023-2028 (%)
6.6 Market opportunity by Product
Exhibit 46: Market opportunity by Product ($ million)
Exhibit 47: Data Table on Market opportunity by Product ($ million)
7 Market Segmentation by Route of Administration
7.1 Market segments
Exhibit 48: Chart on Route of Administration - Market share 2023-2028 (%)
Exhibit 49: Data Table on Route of Administration - Market share 2023-2028 (%)
7.2 Comparison by Route of Administration
Exhibit 50: Chart on Comparison by Route of Administration
Exhibit 51: Data Table on Comparison by Route of Administration
7.3 Oral - Market size and forecast 2023-2028
Exhibit 52: Chart on Oral - Market size and forecast 2023-2028 ($ million)
Exhibit 53: Data Table on Oral - Market size and forecast 2023-2028 ($ million)
Exhibit 54: Chart on Oral - Year-over-year growth 2023-2028 (%)
Exhibit 55: Data Table on Oral - Year-over-year growth 2023-2028 (%)
7.4 Parentral - Market size and forecast 2023-2028
Exhibit 56: Chart on Parentral - Market size and forecast 2023-2028 ($ million)
Exhibit 57: Data Table on Parentral - Market size and forecast 2023-2028 ($ million)
Exhibit 58: Chart on Parentral - Year-over-year growth 2023-2028 (%)
Exhibit 59: Data Table on Parentral - Year-over-year growth 2023-2028 (%)
7.5 Market opportunity by Route of Administration
Exhibit 60: Market opportunity by Route of Administration ($ million)
Exhibit 61: Data Table on Market opportunity by Route of Administration ($ million)
8 Customer Landscape
8.1 Customer landscape overview
Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape
9.1 Geographic segmentation
Exhibit 63: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibit 64: Data Table on Market share By Geographical Landscape 2023-2028 (%)
9.2 Geographic comparison
Exhibit 65: Chart on Geographic comparison
Exhibit 66: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2023-2028
Exhibit 67: Chart on North America - Market size and forecast 2023-2028 ($ million)
Exhibit 68: Data Table on North America - Market size and forecast 2023-2028 ($ million)
Exhibit 69: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibit 70: Data Table on North America - Year-over-year growth 2023-2028 (%)
9.4 Europe - Market size and forecast 2023-2028
Exhibit 71: Chart on Europe - Market size and forecast 2023-2028 ($ million)
Exhibit 72: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
Exhibit 73: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibit 74: Data Table on Europe - Year-over-year growth 2023-2028 (%)
9.5 Asia - Market size and forecast 2023-2028
Exhibit 75: Chart on Asia - Market size and forecast 2023-2028 ($ million)
Exhibit 76: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
Exhibit 77: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibit 78: Data Table on Asia - Year-over-year growth 2023-2028 (%)
9.6 Rest of World (ROW) - Market size and forecast 2023-2028
Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
9.7 US - Market size and forecast 2023-2028
Exhibit 83: Chart on US - Market size and forecast 2023-2028 ($ million)
Exhibit 84: Data Table on US - Market size and forecast 2023-2028 ($ million)
Exhibit 85: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibit 86: Data Table on US - Year-over-year growth 2023-2028 (%)
9.8 Germany - Market size and forecast 2023-2028
Exhibit 87: Chart on Germany - Market size and forecast 2023-2028 ($ million)
Exhibit 88: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
Exhibit 89: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibit 90: Data Table on Germany - Year-over-year growth 2023-2028 (%)
9.9 China - Market size and forecast 2023-2028
Exhibit 91: Chart on China - Market size and forecast 2023-2028 ($ million)
Exhibit 92: Data Table on China - Market size and forecast 2023-2028 ($ million)
Exhibit 93: Chart on China - Year-over-year growth 2023-2028 (%)
Exhibit 94: Data Table on China - Year-over-year growth 2023-2028 (%)
9.10 France - Market size and forecast 2023-2028
Exhibit 95: Chart on France - Market size and forecast 2023-2028 ($ million)
Exhibit 96: Data Table on France - Market size and forecast 2023-2028 ($ million)
Exhibit 97: Chart on France - Year-over-year growth 2023-2028 (%)
Exhibit 98: Data Table on France - Year-over-year growth 2023-2028 (%)
9.11 Japan - Market size and forecast 2023-2028
Exhibit 99: Chart on Japan - Market size and forecast 2023-2028 ($ million)
Exhibit 100: Data Table on Japan - Market size and forecast 2023-2028 ($ million)
Exhibit 101: Chart on Japan - Year-over-year growth 2023-2028 (%)
Exhibit 102: Data Table on Japan - Year-over-year growth 2023-2028 (%)
9.12 Market opportunity By Geographical Landscape
Exhibit 103: Market opportunity By Geographical Landscape ($ million)
Exhibit 104: Data Tables on Market opportunity By Geographical Landscape ($ million)
10 Drivers, Challenges, and Trends
10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 105: Impact of drivers and challenges in 2023 and 2028
10.4 Market trends
11 Vendor Landscape
11.1 Overview
11.2 Vendor landscape
Exhibit 106: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 107: Overview on factors of disruption
11.4 Industry risks
Exhibit 108: Impact of key risks on business
12 Vendor Analysis
12.1 Vendors covered
Exhibit 109: Vendors covered
12.2 Market positioning of vendors
Exhibit 110: Matrix on vendor position and classification
12.3 Anant Pharmaceuticals Pvt. Ltd.
Exhibit 111: Anant Pharmaceuticals Pvt. Ltd. - Overview
Exhibit 112: Anant Pharmaceuticals Pvt. Ltd. - Product / Service
Exhibit 113: Anant Pharmaceuticals Pvt. Ltd. - Key offerings
12.4 Apotex Inc.
Exhibit 114: Apotex Inc. - Overview
Exhibit 115: Apotex Inc. - Product / Service
Exhibit 116: Apotex Inc. - Key offerings
12.5 BrainsWay Ltd.
Exhibit 117: BrainsWay Ltd. - Overview
Exhibit 118: BrainsWay Ltd. - Product / Service
Exhibit 119: BrainsWay Ltd. - Key offerings
12.6 Eli Lilly and Co.
Exhibit 120: Eli Lilly and Co. - Overview
Exhibit 121: Eli Lilly and Co. - Product / Service
Exhibit 122: Eli Lilly and Co. - Key news
Exhibit 123: Eli Lilly and Co. - Key offerings
12.7 Eridanus
Exhibit 124: Eridanus - Overview
Exhibit 125: Eridanus - Product / Service
Exhibit 126: Eridanus - Key offerings
12.8 flamingopharma.com
Exhibit 127: flamingopharma.com - Overview
Exhibit 128: flamingopharma.com - Product / Service
Exhibit 129: flamingopharma.com - Key offerings
12.9 GlaxoSmithKline Plc
Exhibit 130: GlaxoSmithKline Plc - Overview
Exhibit 131: GlaxoSmithKline Plc - Business segments
Exhibit 132: GlaxoSmithKline Plc - Key news
Exhibit 133: GlaxoSmithKline Plc - Key offerings
Exhibit 134: GlaxoSmithKline Plc - Segment focus
12.10 H Lundbeck AS
Exhibit 135: H Lundbeck AS - Overview
Exhibit 136: H Lundbeck AS - Product / Service
Exhibit 137: H Lundbeck AS - Key offerings
12.11 Jazz Pharmaceuticals Plc
Exhibit 138: Jazz Pharmaceuticals Plc - Overview
Exhibit 139: Jazz Pharmaceuticals Plc - Product / Service
Exhibit 140: Jazz Pharmaceuticals Plc - Key news
Exhibit 141: Jazz Pharmaceuticals Plc - Key offerings
12.12 Lepu Medical Technology Beijing Co. Ltd.
Exhibit 142: Lepu Medical Technology Beijing Co. Ltd. - Overview
Exhibit 143: Lepu Medical Technology Beijing Co. Ltd. - Product / Service
Exhibit 144: Lepu Medical Technology Beijing Co. Ltd. - Key offerings
12.13 Lifecare Neuro Products Ltd.
Exhibit 145: Lifecare Neuro Products Ltd. - Overview
Exhibit 146: Lifecare Neuro Products Ltd. - Key offerings
12.14 Neurocon Inc.
Exhibit 147: Neurocon Inc. - Overview
Exhibit 148: Neurocon Inc. - Product / Service
Exhibit 149: Neurocon Inc. - Key offerings
12.15 Novartis AG
Exhibit 150: Novartis AG - Overview
Exhibit 151: Novartis AG - Business segments
Exhibit 152: Novartis AG - Key offerings
Exhibit 153: Novartis AG - Segment focus
12.16 Pfizer Inc.
Exhibit 154: Pfizer Inc. - Overview
Exhibit 155: Pfizer Inc. - Product / Service
Exhibit 156: Pfizer Inc. - Key news
Exhibit 157: Pfizer Inc. - Key offerings
12.17 Wellona Pharma
Exhibit 158: Wellona Pharma - Overview
Exhibit 159: Wellona Pharma - Product / Service
Exhibit 160: Wellona Pharma - Key offerings
13 Appendix
13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 161: Inclusions checklist
Exhibit 162: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 163: Currency conversion rates for US$
13.4 Research methodology
Exhibit 164: Research methodology
Exhibit 165: Validation techniques employed for market sizing
Exhibit 166: Information sources
13.5 List of abbreviations
Exhibit 167: List of abbreviations
List of Exhibits
Exhibits 1: Executive Summary - Chart on Market Overview
Exhibits 2: Executive Summary - Data Table on Market Overview
Exhibits 3: Executive Summary - Chart on Global Market Characteristics
Exhibits 4: Executive Summary - Chart on Market By Geographical Landscape
Exhibits 5: Executive Summary - Chart on Market Segmentation by Product
Exhibits 6: Executive Summary - Chart on Market Segmentation by Route of Administration
Exhibits 7: Executive Summary - Chart on Incremental Growth
Exhibits 8: Executive Summary - Data Table on Incremental Growth
Exhibits 9: Executive Summary - Chart on Vendor Market Positioning
Exhibits 10: Parent market
Exhibits 11: Market Characteristics
Exhibits 12: Offerings of vendors included in the market definition
Exhibits 13: Market segments
Exhibits 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
Exhibits 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
Exhibits 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits 18: Historic Market Size - Data Table on global obsessive-compulsive disorder drugs market 2018 - 2022 ($ million)
Exhibits 19: Historic Market Size - Product Segment 2018 - 2022 ($ million)
Exhibits 20: Historic Market Size - Route of Administration Segment 2018 - 2022 ($ million)
Exhibits 21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
Exhibits 22: Historic Market Size - Country Segment 2018 - 2022 ($ million)
Exhibits 23: Five forces analysis - Comparison between 2023 and 2028
Exhibits 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
Exhibits 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
Exhibits 26: Threat of new entrants - Impact of key factors in 2023 and 2028
Exhibits 27: Threat of substitutes - Impact of key factors in 2023 and 2028
Exhibits 28: Threat of rivalry - Impact of key factors in 2023 and 2028
Exhibits 29: Chart on Market condition - Five forces 2023 and 2028
Exhibits 30: Chart on Product - Market share 2023-2028 (%)
Exhibits 31: Data Table on Product - Market share 2023-2028 (%)
Exhibits 32: Chart on Comparison by Product
Exhibits 33: Data Table on Comparison by Product
Exhibits 34: Chart on SSRI - Market size and forecast 2023-2028 ($ million)
Exhibits 35: Data Table on SSRI - Market size and forecast 2023-2028 ($ million)
Exhibits 36: Chart on SSRI - Year-over-year growth 2023-2028 (%)
Exhibits 37: Data Table on SSRI - Year-over-year growth 2023-2028 (%)
Exhibits 38: Chart on TSA - Market size and forecast 2023-2028 ($ million)
Exhibits 39: Data Table on TSA - Market size and forecast 2023-2028 ($ million)
Exhibits 40: Chart on TSA - Year-over-year growth 2023-2028 (%)
Exhibits 41: Data Table on TSA - Year-over-year growth 2023-2028 (%)
Exhibits 42: Chart on Others - Market size and forecast 2023-2028 ($ million)
Exhibits 43: Data Table on Others - Market size and forecast 2023-2028 ($ million)
Exhibits 44: Chart on Others - Year-over-year growth 2023-2028 (%)
Exhibits 45: Data Table on Others - Year-over-year growth 2023-2028 (%)
Exhibits 46: Market opportunity by Product ($ million)
Exhibits 47: Data Table on Market opportunity by Product ($ million)
Exhibits 48: Chart on Route of Administration - Market share 2023-2028 (%)
Exhibits 49: Data Table on Route of Administration - Market share 2023-2028 (%)
Exhibits 50: Chart on Comparison by Route of Administration
Exhibits 51: Data Table on Comparison by Route of Administration
Exhibits 52: Chart on Oral - Market size and forecast 2023-2028 ($ million)
Exhibits 53: Data Table on Oral - Market size and forecast 2023-2028 ($ million)
Exhibits 54: Chart on Oral - Year-over-year growth 2023-2028 (%)
Exhibits 55: Data Table on Oral - Year-over-year growth 2023-2028 (%)
Exhibits 56: Chart on Parentral - Market size and forecast 2023-2028 ($ million)
Exhibits 57: Data Table on Parentral - Market size and forecast 2023-2028 ($ million)
Exhibits 58: Chart on Parentral - Year-over-year growth 2023-2028 (%)
Exhibits 59: Data Table on Parentral - Year-over-year growth 2023-2028 (%)
Exhibits 60: Market opportunity by Route of Administration ($ million)
Exhibits 61: Data Table on Market opportunity by Route of Administration ($ million)
Exhibits 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits 63: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibits 64: Data Table on Market share By Geographical Landscape 2023-2028 (%)
Exhibits 65: Chart on Geographic comparison
Exhibits 66: Data Table on Geographic comparison
Exhibits 67: Chart on North America - Market size and forecast 2023-2028 ($ million)
Exhibits 68: Data Table on North America - Market size and forecast 2023-2028 ($ million)
Exhibits 69: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibits 70: Data Table on North America - Year-over-year growth 2023-2028 (%)
Exhibits 71: Chart on Europe - Market size and forecast 2023-2028 ($ million)
Exhibits 72: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
Exhibits 73: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibits 74: Data Table on Europe - Year-over-year growth 2023-2028 (%)
Exhibits 75: Chart on Asia - Market size and forecast 2023-2028 ($ million)
Exhibits 76: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
Exhibits 77: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibits 78: Data Table on Asia - Year-over-year growth 2023-2028 (%)
Exhibits 79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibits 80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibits 81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibits 82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibits 83: Chart on US - Market size and forecast 2023-2028 ($ million)
Exhibits 84: Data Table on US - Market size and forecast 2023-2028 ($ million)
Exhibits 85: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibits 86: Data Table on US - Year-over-year growth 2023-2028 (%)
Exhibits 87: Chart on Germany - Market size and forecast 2023-2028 ($ million)
Exhibits 88: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
Exhibits 89: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibits 90: Data Table on Germany - Year-over-year growth 2023-2028 (%)
Exhibits 91: Chart on China - Market size and forecast 2023-2028 ($ million)
Exhibits 92: Data Table on China - Market size and forecast 2023-2028 ($ million)
Exhibits 93: Chart on China - Year-over-year growth 2023-2028 (%)
Exhibits 94: Data Table on China - Year-over-year growth 2023-2028 (%)
Exhibits 95: Chart on France - Market size and forecast 2023-2028 ($ million)
Exhibits 96: Data Table on France - Market size and forecast 2023-2028 ($ million)
Exhibits 97: Chart on France - Year-over-year growth 2023-2028 (%)
Exhibits 98: Data Table on France - Year-over-year growth 2023-2028 (%)
Exhibits 99: Chart on Japan - Market size and forecast 2023-2028 ($ million)
Exhibits 100: Data Table on Japan - Market size and forecast 2023-2028 ($ million)
Exhibits 101: Chart on Japan - Year-over-year growth 2023-2028 (%)
Exhibits 102: Data Table on Japan - Year-over-year growth 2023-2028 (%)
Exhibits 103: Market opportunity By Geographical Landscape ($ million)
Exhibits 104: Data Tables on Market opportunity By Geographical Landscape ($ million)
Exhibits 105: Impact of drivers and challenges in 2023 and 2028
Exhibits 106: Overview on Criticality of inputs and Factors of differentiation
Exhibits 107: Overview on factors of disruption
Exhibits 108: Impact of key risks on business
Exhibits 109: Vendors covered
Exhibits 110: Matrix on vendor position and classification
Exhibits 111: Anant Pharmaceuticals Pvt. Ltd. - Overview
Exhibits 112: Anant Pharmaceuticals Pvt. Ltd. - Product / Service
Exhibits 113: Anant Pharmaceuticals Pvt. Ltd. - Key offerings
Exhibits 114: Apotex Inc. - Overview
Exhibits 115: Apotex Inc. - Product / Service
Exhibits 116: Apotex Inc. - Key offerings
Exhibits 117: BrainsWay Ltd. - Overview
Exhibits 118: BrainsWay Ltd. - Product / Service
Exhibits 119: BrainsWay Ltd. - Key offerings
Exhibits 120: Eli Lilly and Co. - Overview
Exhibits 121: Eli Lilly and Co. - Product / Service
Exhibits 122: Eli Lilly and Co. - Key news
Exhibits 123: Eli Lilly and Co. - Key offerings
Exhibits 124: Eridanus - Overview
Exhibits 125: Eridanus - Product / Service
Exhibits 126: Eridanus - Key offerings
Exhibits 127: flamingopharma.com - Overview
Exhibits 128: flamingopharma.com - Product / Service
Exhibits 129: flamingopharma.com - Key offerings
Exhibits 130: GlaxoSmithKline Plc - Overview
Exhibits 131: GlaxoSmithKline Plc - Business segments
Exhibits 132: GlaxoSmithKline Plc - Key news
Exhibits 133: GlaxoSmithKline Plc - Key offerings
Exhibits 134: GlaxoSmithKline Plc - Segment focus
Exhibits 135: H Lundbeck AS - Overview
Exhibits 136: H Lundbeck AS - Product / Service
Exhibits 137: H Lundbeck AS - Key offerings
Exhibits 138: Jazz Pharmaceuticals Plc - Overview
Exhibits 139: Jazz Pharmaceuticals Plc - Product / Service
Exhibits 140: Jazz Pharmaceuticals Plc - Key news
Exhibits 141: Jazz Pharmaceuticals Plc - Key offerings
Exhibits 142: Lepu Medical Technology Beijing Co. Ltd. - Overview
Exhibits 143: Lepu Medical Technology Beijing Co. Ltd. - Product / Service
Exhibits 144: Lepu Medical Technology Beijing Co. Ltd. - Key offerings
Exhibits 145: Lifecare Neuro Products Ltd. - Overview
Exhibits 146: Lifecare Neuro Products Ltd. - Key offerings
Exhibits 147: Neurocon Inc. - Overview
Exhibits 148: Neurocon Inc. - Product / Service
Exhibits 149: Neurocon Inc. - Key offerings
Exhibits 150: Novartis AG - Overview
Exhibits 151: Novartis AG - Business segments
Exhibits 152: Novartis AG - Key offerings
Exhibits 153: Novartis AG - Segment focus
Exhibits 154: Pfizer Inc. - Overview
Exhibits 155: Pfizer Inc. - Product / Service
Exhibits 156: Pfizer Inc. - Key news
Exhibits 157: Pfizer Inc. - Key offerings
Exhibits 158: Wellona Pharma - Overview
Exhibits 159: Wellona Pharma - Product / Service
Exhibits 160: Wellona Pharma - Key offerings
Exhibits 161: Inclusions checklist
Exhibits 162: Exclusions checklist
Exhibits 163: Currency conversion rates for US$
Exhibits 164: Research methodology
Exhibits 165: Validation techniques employed for market sizing
Exhibits 166: Information sources
Exhibits 167: List of abbreviations

Executive Summary

The publisher recognizes the following companies as the key players in the global obsessive-compulsive disorder drugs market: Alembic Pharmaceuticals Ltd., Anant Pharmaceuticals Pvt. Ltd., Apotex Inc., BrainsWay Ltd., Dellwich Healthcare LLP, Eli Lilly and Co., Eridanus, flamingopharma.com, GlaxoSmithKline Plc, H Lundbeck AS, Jabs Biotech, Jazz Pharmaceuticals Plc, Kabir Lifesciences, Lepu Medical Technology Beijing Co. Ltd., Lifecare Neuro Products Ltd., Novartis AG, Omeros Corp., Pfizer Inc., SERVOMAX Ltd., Wellona Pharma, and Neurocon Inc..

Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is increased use of off-label therapies.'

According to the report, one of the major drivers for this market is the rising prevalence of OCD.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Alembic Pharmaceuticals Ltd.
  • Anant Pharmaceuticals Pvt. Ltd.
  • Apotex Inc.
  • BrainsWay Ltd.
  • Dellwich Healthcare LLP
  • Eli Lilly and Co.
  • Eridanus
  • flamingopharma.com
  • GlaxoSmithKline Plc
  • H Lundbeck AS
  • Jabs Biotech
  • Jazz Pharmaceuticals Plc
  • Kabir Lifesciences
  • Lepu Medical Technology Beijing Co. Ltd.
  • Lifecare Neuro Products Ltd.
  • Novartis AG
  • Omeros Corp.
  • Pfizer Inc.
  • SERVOMAX Ltd.
  • Wellona Pharma
  • Neurocon Inc.